Glaucoma Journal Club

Darin Curtiss

Beacon College · Astellas Pharma (United States)

OpenAlexGoogle ScholarResearchGateScopus

In this database

1

2025

DB Citations

16

across indexed articles

h-index

3

OpenAlex (all works)

Total Citations

42

OpenAlex (all works)

4 total publications (OpenAlex)2 i10-index

1 article in Glaucoma Journal Club

Subretinal Gene Therapy Drug AGTC-501 for XLRP Phase 1/2 Multicenter Study (HORIZON): 24-Month Safety and Efficacy Results.

Preliminary efficacy was observed at the maximum tolerated dose. Further studies are warranted to assess long-term safety and efficacy of AGTC-501 for XLRP treatment.

American journal of ophthalmology2025 Mar16 citations
visual-fieldneuroprotection